



## **SciGen and NasVax Execute a Joint Development & Commercialization Agreement.**

**10<sup>th</sup> December 2007:** SciGen Limited (ASX:SIE) announces that it has executed a Joint Development & Commercialization Agreement with NasVax Ltd. to jointly develop and commercialize a prophylactic intranasal Hepatitis B vaccine. The product subject of the collaboration is under development, and will combine antigens for immunization against Hepatitis B produced by SciGen with Nasvax unique adjuvant technology, and will be directed towards intranasal delivery. Moreover, SciGen was granted an option, exercisable during the 12 months after the execution of the Agreement, to obtain a non-exclusive license to use Nasvax technology to develop an intramuscular prophylactic Hepatitis B vaccine under conditions to be mutually determined in the future.

According to Mr. Saul Mashaal, Chairman & CEO of SciGen Ltd. this Agreement provides new opportunities in respect to the development of a new delivery for the Hepatitis B vaccine, especially in newborn and children, by combining the unique technologies of both companies that will address the market's demand for improved efficiency, reduction of the amount of repetitions necessary for vaccination and intranasal immunization.

The world market for Hepatitis vaccines is presently estimated at about 1.3 Billion U.S. Dollars.

### **About SciGen:**

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

For personal use only



SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands.

**About NasVax:**

NasVax (TASE: NSVX) develops technology for improving vaccinations. The Company's unique technology is based on positively charged sphingolipids biomolecules used as adjuvants (materials which stimulate the immune system to create a stronger more efficient immune response), and for delivery. The platform, which the Company is developing, enables vaccination through the nose (intranasal) as well as intramuscular or subcutaneous injection.

The Company's leading project is currently in clinical trial (Phase I/IIa) and is for the development of an improved vaccine against the influenza virus, which has shown in pre-clinical trials in animals, far better immune responses and better protection from the disease compared to a commercially available vaccine. Additionally, the Company is currently performing pre-clinical trials on vaccines against Anthrax, Avian flu and Hepatitis B. In respect of these applications as well, the Company has demonstrated an increase in the vaccines efficacy when injected intramuscularly or delivered by spray intranasally.

NasVax's core technology is expected to enable the improvement of vaccinations for many indications, both for the prevention of infectious diseases (bacterial and viral) and in other fields, which involve technologies for various medical vaccinations.

The Company was founded on August 2004, and went public in December of 2005.

**Further information:**

Company – Investor Relations	Company
Ms. Maria Aroyan SciGen Australia +61 2 9485 1800 email: mariaaroyan@scigen.com.au	Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9485 1800 +65 9630 5691 (Mobile)

For personal use only